Oncology Institute (NASDAQ:TOI) Director Sells $200,501.00 in Stock

Key Points

• Director Mohit Kaushal sold 57,286 shares on April 14 for $200,501 and another 38,433 shares on April 16 for $134,515.50 under a pre‑arranged Rule 10b5-1 plan, cutting his stake by 21.35% to 211,016 shares.
• TOI shares traded around $3.54 midday with a market cap of about $349.9M, a one‑year range of $1.91–$4.88, and a negative P/E of -6.32.
• Analysts hold a consensus "Moderate Buy" with a $7.00 price target, and the company recently beat estimates with Q1 EPS of ($0.06) and revenue of $141.96M.

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Mohit Kaushal sold 57,286 shares of the stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $3.50, for a total value of $200,501.00. Following the completion of the sale, the director directly owned 211,016 shares of the company's stock, valued at $738,556. The trade was a 21.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mohit Kaushal also recently made the following trade(s):

• On Thursday, April 16th, Mohit Kaushal sold 38,433 shares of Oncology Institute stock. The shares were sold at an average price of $3.50, for a total value of $134,515.50.

Oncology Institute Price Performance

Shares of TOI traded up $0.11 during midday trading on Thursday, hitting $3.54. 2,190,265 shares of the company traded hands, compared to its average volume of 1,548,966. The Oncology Institute, Inc. has a one year low of $1.91 and a one year high of $4.88. The firm has a market cap of $349.89 million, a P/E ratio of -6.32 and a beta of 0.17. The stock has a 50-day moving average of $2.95 and a 200-day moving average of $3.38.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The firm had revenue of $141.96 million during the quarter, compared to the consensus estimate of $139.78 million.

Institutional Investors Weigh In On Oncology Institute

Several large investors have recently made changes to their positions in TOI. Goldman Sachs Group Inc. acquired a new position in Oncology Institute in the first quarter worth approximately $131,000. Geode Capital Management LLC lifted its stake in shares of Oncology Institute by 231.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company's stock valued at $2,623,000 after purchasing an additional 893,696 shares during the last quarter. Cetera Investment Advisers lifted its stake in shares of Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock valued at $36,000 after purchasing an additional 4,545 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Oncology Institute by 51,631.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 27,935 shares of the company's stock worth $57,000 after acquiring an additional 27,881 shares during the period. Finally, New York State Common Retirement Fund bought a new position in Oncology Institute in the 2nd quarter worth $92,000. Institutional investors and hedge funds own 36.86% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TOI shares. BTIG Research restated a "buy" rating and issued a $7.00 price target on shares of Oncology Institute in a research report on Monday, March 9th. Needham & Company LLC restated a "buy" rating and issued a $5.00 target price on shares of Oncology Institute in a research note on Monday, March 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oncology Institute in a report on Wednesday, January 21st. Finally, B. Riley Financial raised their price target on Oncology Institute from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.